8-K: Calidi Biotherapeutics Receives FDA Clearance for CLD-101 Clinical Trial in High-Grade Glioma

Calidi Biotherapeutics has announced FDA clearance for its CLD-101 clinical trial in high-grade glioma, marking a significant step in the development of its novel stem-cell based immunotherapy.

Summary

• Calidi Biotherapeutics has received FDA clearance for Northwestern University's Investigational New Drug (IND) application for CLD-101.
• CLD-101 is a novel stem-cell based platform designed to deliver oncolytic viruses to tumors.
• The Phase 1b/2 clinical trial is expected to begin in late 2024 at Northwestern University.
• The trial will evaluate the safety and feasibility of multiple doses of CLD-101 in patients with newly diagnosed high-grade glioma.
• Eligible patients will receive CLD-101 in addition to surgery, radiation therapy, and chemotherapy.
• A previous Phase 1 study of CLD-101 showed a median progression-free survival of 9.05 months and overall survival of 18.4 months.
• Calidi is also conducting a Phase 1 trial of CLD-101 for recurrent high-grade glioma in collaboration with City of Hope.
• Interim clinical data from the City of Hope trial is expected in the first half of 2025.
• City of Hope received $5.3 million from the California Institute for Regenerative Medicine (CIRM) to support CLD-101 research in ovarian cancer.

Sentiment

Score: 8

Explanation: The document conveys a positive sentiment due to the FDA clearance, promising early trial results, and the potential of the technology. However, there are risks associated with clinical trials and funding, which temper the overall sentiment.

Positives

• FDA clearance of the IND application is a significant regulatory milestone.
• The previous Phase 1 trial showed promising results with a median progression-free survival of 9.05 months and overall survival of 18.4 months.
• The technology has potential for treating difficult cancers like high-grade glioma.
• The company has multiple ongoing trials and collaborations.

Negatives

• The document does not explicitly state any negative aspects of the trial or the company.

Risks

• The company may not be able to raise sufficient capital to support its clinical trials.
• Early results of clinical trials may not predict final results.
• Clinical outcomes may change following more comprehensive review of the data.
• The company may not receive FDA approval for its therapeutic candidates.

Future Outlook

The company anticipates commencing a Phase 1b/2 clinical trial in late 2024 and reporting interim clinical data from another trial in the first half of 2025. The company is also continuing to develop its novel immunotherapies.

Management Comments

• Maciej S. Lesniak, MD, stated that the research suggests the potential of CLD-101 in the treatment of brain cancer.
• Alfred Yung, MD, expressed being impressed by Dr. Lesniak's work and pleased by the FDA clearance.
• Allan Camaisa, CEO and Chairman of the Board of Calidi, stated that the company believes CLD-101 offers a novel therapeutic option for patients with high-grade glioma.

Industry Context

This announcement is significant in the context of the broader immuno-oncology field, where novel approaches like oncolytic viruses and stem cell therapies are being explored to treat difficult cancers. The FDA clearance allows Calidi to advance its technology into further clinical trials, potentially impacting the treatment landscape for high-grade glioma.

Comparison to Industry Standards

• The median progression-free survival of 9.05 months and overall survival of 18.4 months in the previous Phase 1 trial are promising when compared to the typical 5-10% five-year survival rate for adults with high-grade glioma.
• While specific comparisons to other companies' results are not provided in the document, the use of stem cell-based delivery of oncolytic viruses is a novel approach that differentiates Calidi from traditional cancer therapies.
• Companies like BioNTech and Moderna have shown success with mRNA-based cancer therapies, while others like Amgen and Kite Pharma are focused on CAR T-cell therapies. Calidi's approach is distinct, focusing on oncolytic viruses delivered by stem cells.

Stakeholder Impact

• Shareholders may view the FDA clearance positively, potentially increasing the company's stock value.
• Patients with high-grade glioma may benefit from a new treatment option.
• Employees may be motivated by the progress of the company's research.
• The company's partners, such as Northwestern University and City of Hope, will be impacted by the progress of the clinical trials.

Next Steps

• Commencement of the Phase 1b/2 clinical trial at Northwestern University in late 2024.
• Reporting of interim clinical data from the City of Hope trial in the first half of 2025.

Key Dates

Keywords

CLD-101, High-Grade Glioma, Immunotherapy, Oncolytic Virus, Stem Cell, Clinical Trial, FDA Clearance, Neuro-oncology, Virotherapy, Cancer